Stockscreener 앱 받기
1.10
3.51%
-0.04
시간 외 거래:
1.14
0.04
+3.64%
전일 마감가:
$1.14
열려 있는:
$1.08
하루 거래량:
531.89K
Relative Volume:
0.03
시가총액:
$7.88M
수익:
$6.59M
순이익/손실:
$-18.12M
주가수익비율:
-0.1163
EPS:
-9.4605
순현금흐름:
$-11.45M
1주 성능:
-9.09%
1개월 성능:
-9.84%
6개월 성능:
-36.60%
1년 성능:
-79.25%
1일 변동 폭
$1.08
$1.25
1주일 범위
$1.035
$1.333
52주 변동 폭
$0.25
$7.35
Hcw Biologics Inc Stock (HCWB) Company Profile
명칭
Hcw Biologics Inc
전화
954-842-2024
주소
2929 N COMMERCE PKWY, MIRAMAR
Compare HCWB vs VRTX, REGN, ARGX, ALNY, RVMD
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
HCWB
Hcw Biologics Inc
|
1.10 | 8.74M | 6.59M | -18.12M | -11.45M | -9.4605 |
VRTX
Vertex Pharmaceuticals Inc
|
458.99 | 114.33B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
607.93 | 64.47B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
892.26 | 54.99B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
282.72 | 38.42B | 4.29B | 577.22M | 641.34M | 4.2086 |
RVMD
Revolution Medicines Inc
|
157.77 | 34.03B | 742.00K | -1.37B | -1.07B | -7.0731 |
Hcw Biologics Inc 주식(HCWB)의 최신 뉴스
HCW Biologics Inc. Files Form 8-K with SEC Detailing Company and Stock Information - Minichart
HCW Biologics (HCWB) AGM 2026 Summary - Quartr
Shareholders back HCW Biologics (NASDAQ: HCWB) 2026 board slate - Stock Titan
HCW Biologics takes back rights to commercial-ready reagents - MSN
HCW Biologics Inc Stock Short Interest Rises to 58.43% - Quiver Quantitative
HCWB Announces Selling Shareholder Plans for 5.69M Shares - GuruFocus
HCW Biologics Registers Resale of Up to 5.7 Million Shares - marketscreener.com
HCW Biologics Proposed Resale Of Up To 5.69 Million Shares Of Common Stock - TradingView
HCW Biologics (HCWB) files S-1 for resale of 5.69M PIPE shares and warrants - Stock Titan
HCW Biologics Inc. (HCWB) Holds Steady as Shares Consolidate Between Key Support and ResistanceWeak Sell Signals - newsline.com
Nasdaq Deadline Looms for HCW Biologics as Stock Slips Toward $1 Mark - Bez Kabli
Clark Hill Advises HCW Biologics in $4.0 Million PIPE Offering | News & Events | Clark Hill PLC - Clark Hill
HCW Biologics Wins Nasdaq Extension to Avoid Delisting - The Globe and Mail
HCWB Stock Price, Quote & Chart | HCW BIOLOGICS INC (NASDAQ:HCWB) - ChartMill
HCW Biologics Inc. Files Form 8-K with SEC: Company Details, Stock Information, and Emerging Growth Status - Minichart
Nasdaq grants HCW Biologics extension to regain minimum bid compliance By Investing.com - Investing.com Canada
Nasdaq grants HCW Biologics extension to regain minimum bid compliance - Investing.com UK
HCW Biologics Disclosed Failure to Satisfy a Continued Listing Rule or Standard - TradingView
HCW Biologics (HCWB) granted Nasdaq extension to fix $1 bid price deficiency - Stock Titan
MSN Money - MSN
HCW Biologics, Inc. Financial Disclosures & SEC Filings - TradingView
Maxim Group Maintains HCW Biologics(HCWB.US) With Buy Rating, Raises Target Price to $5 - Moomoo
Maxim Group Maintains HCW Biologics(HCWB.US) With Buy Rating, Maintains Target Price $5 - 富途牛牛
HCWB Maintained by Maxim Group -- Price Target Raised to $5.00 - GuruFocus
Top insider buys and sells disclosed for Wednesday By Investing.com - Investing.com UK
HCW Biologics CFO Rebecca Byam buys $20,000 in common stock By Investing.com - Investing.com Canada
HCW Biologics CEO Wong buys $159,999 in common stock By Investing.com - Investing.com South Africa
HCW Biologics CEO Wong buys $159,999 in common stock - Investing.com
HCW Biologics CFO Rebecca Byam buys $20,000 in common stock - Investing.com
HCW Biologics director Scott T. Garrett purchases $250,000 in stock - Investing.com
HCW Biologics director Scott T. Garrett purchases $250,000 in stock By Investing.com - Investing.com Canada
HCW Biologics (HCWB) CEO boosts stake with stock and warrant buys - Stock Titan
HCW Biologics (HCWB) director adds common shares and long-dated warrants - Stock Titan
HCW Biologics CFO buys shares and warrants | HCWB Insider Trading - Stock Titan
HCWB Regains Ex Vivo Rights for Key Compounds - GuruFocus
HCW Biologics regains ex vivo rights to CAR-T therapy reagents - Investing.com UK
HCW Biologics regains ex vivo rights to CAR-T therapy reagents By Investing.com - Investing.com South Africa
HCW Biologics (NASDAQ: HCWB) ends Wugen license, keeps 2.2M shares - Stock Titan
HCW Biologics to regain full rights for two commercial-ready reagents from Wugen - marketscreener.com
HCW Biologics To Regain Full Rights For Two Commercial-Ready Reagents From Wugen - TradingView
HCW Biologics Exercised Option to Regain Full Rights for Two Commercial-Ready Reagents from Wugen - GlobeNewswire
Hcw Biologics Inc (HCWB) 재무 분석
매출
순이익
현금흐름
주당 순 이익
Hcw Biologics Inc 주식 (HCWB) 내부자 거래
| 내부자 거래 | 관계 | 날짜 | 거래 | 비용 | #주식 | 가치 ($) | #주식 총계 |
|---|---|---|---|---|---|---|---|
| GARRETT SCOTT T | Director |
May 22 '26 |
Buy |
1.41 |
177,936 |
250,000 |
203,441 |
| Byam Rebecca | Chief Financial Officer |
May 22 '26 |
Buy |
1.41 |
14,235 |
20,000 |
57,245 |
2.60%
0.94%
자본화:
|
볼륨(24시간):